Edinburgh's Western General Hospital — home to one of Scotland's leading haematology and oncology programmes — manages CML and GIST patients across the Lothian region and beyond. For Edinburgh patients accessing private oncology at the Murrayfield Hospital or requiring supply outside NHS Scotland channels, Imatib 400mg delivers identical clinical outcomes to brand Glivec at dramatically reduced cost.
Scotland's SMC (Scottish Medicines Consortium) makes independent drug coverage decisions from NHS England's NICE, meaning some patients in Edinburgh face different access pathways than those in London. Generic Imatib provides a reliable private supply pathway for Scottish patients facing SMC coverage restrictions or administrative delays in accessing their approved therapy.
Visit medshopy.com or WhatsApp +91 82650 41513 for Edinburgh supply.
Scotland's SMC (Scottish Medicines Consortium) makes independent drug coverage decisions from NHS England's NICE, meaning some patients in Edinburgh face different access pathways than those in London. Generic Imatib provides a reliable private supply pathway for Scottish patients facing SMC coverage restrictions or administrative delays in accessing their approved therapy.
Visit medshopy.com or WhatsApp +91 82650 41513 for Edinburgh supply.
What are second and third generation TKIs and when are they used instead of Imatinib for CML?Second-generation TKIs — Dasatinib (Sprycel) and Nilotinib (Tasigna) — were developed to overcome Imatinib resistance and achieve faster, deeper molecular remissions. They're used when patients develop resistance to Imatinib (detected by rising BCR-ABL levels), when specific resistance mutations are found, or in some guidelines as upfront first-line therapy when achieving deep molecular remission (aiming for treatment-free remission) is a treatment goal. Third-generation Ponatinib (Iclusig) targets the most resistant T315I mutation that neither first nor second-generation TKIs can overcome. Asciminib (Scemblix) is a newer STAMP inhibitor targeting a completely different binding site on BCR-ABL, approved for specific resistance situations. Edinburgh's haematologists select among these based on resistance testing, patient-specific factors, and treatment goals.
